Sareum Holdings (SAR)
20/12/2017 - 11:00 RNS
RNS Number: 9211Z Sareum Holdings PLC 20 December 2017 (AIM: SAR) 20 December 2017 SAREUM HOLDINGS PLC ("Sareum" or the "Company") Issue of Options The Company announces that it granted on 19 December 2017 the following share options (the "Options") to Dr Tim Mitchell, Chief Executive Officer, Dr John Reader, Chief Scientific Officer and ...
19/12/2017 - 07:59 StockMarketWire
Sareum announced that the Japanese Patent Office granted a patent for inventions associated with Sareum's TYK2 kinase ...
19/12/2017 - 07:00 RNS
RNS Number: 6985Z Sareum Holdings PLC 19 December 2017 (AIM: SAR) 19 December 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Patent Grants in Japan and China for Sareum's TYK2 Inhibitors Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Japanese Patent Office has grante...
14/12/2017 - 11:01 RNS
RNS Number: 3728Z Sareum Holdings PLC 14 December 2017 (AIM: SAR) 14 December 2017 Sareum Holdings plc ("Sareum" or "the Company") Results of AGM Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting today and all resolutions were duly passed. -Ends- For furth...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment